<DOC>
	<DOCNO>NCT01858259</DOCNO>
	<brief_summary>Systemic sclerosis ( SSc ) orphan , multiorgan disease affect connective tissue skin internal organ . Interstitial lung disease frequent morbidity mortality-driving manifestation systemic sclerosis . This observational trial ( OT ) part collaborative project `` DeSScipher '' , one five OTs decipher optimal management systemic sclerosis . Aim observational try identify : - The state clinical practice Europe prevention treatment interstitial lung disease impact lung function disease progression - The potential predictor confounders response therapy</brief_summary>
	<brief_title>Treatment Prevention Progression Interstitial Lung Disease Systemic Sclerosis</brief_title>
	<detailed_description>Patients routinely evaluate every 3 month 12-months period medical history , physical examination , pulmonary function test , VAS lung score SF-36 , SHAQ . Also , medication possible medication change record .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Diagnosis fo SSc accord ACR/EULAR criterion adult PRES/ACR/EULAR criterion juvenile SSc patient SSc patient proven ILD ( Xray CT scan ) Treatment standard dosages accord current practice ( ) cyclophosphamide , ( ii ) azathioprine , ( iii ) mycophenolate mofetil , ( iv ) methotrexate , ( v ) therapy Exclusion Criterion : Patients previous exposure silica asbestos</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>